Precision BioSciences Doses First Patient in PBGENE-DMD Gene-Editing Trial
Precision BioSciences disclosed that the first participant received PBGENE-DMD in the Phase 1/2a FUNCTION-DMD trial. The program uses two ARCUS nucleases delivered in one AAV vector to excise DMD exons 45–55 and create an…
